The ethics of expanding access to cheaper, less effective treatments.
Department of Strategy, Economics, Ethics, and Public Policy, McDonough School of Business, Georgetown University, Washington, DC, USA.
Govind C
GC
Persad
Office of the Provost, Department of Medical Ethics and Health Policy, Department of Health Care Management, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; The Wharton School, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: MEHPchair@upenn.edu.
Ezekiel J
EJ
Emanuel
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D019049:Developed Countries; D003906:Developing Countries; D004334:Drug Administration Schedule; D028663:Ethical Theory; D014943:Global Health / Q000191:economics / Q000941:ethics* / Q000592:standards / Q000639:trends; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics*; D006297:Health Services Accessibility / Q000191:economics* / Q000941:ethics* / Q000592:standards / Q000639:trends; D006801:Humans; D013019:South Africa; D018119:Stavudine / Q000191:economics / Q000627:therapeutic use; D000068698:Tenofovir / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014944:World Health Organization; D015215:Zidovudine / Q000191:economics / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015215:Zidovudine; D000068698:Tenofovir; D018119:Stavudine